Skip to main content
OpenTrials
Completed

NCT Number: NCT05216419

Prevention of Postoperative Hypocalcemia of Oral Vitamin D Supplementation Before Total Thyroidectomy

The hypocalcemia after total thyroidectomy is one of common surgical complications. It may be asymptomatic, but patients can complain of dysfunction around the mouth or extremities, stiffness or convulsion in severe cases. The incidence of transient hypocalcemia was 6.9-46%, and permanent hypocalcemia was reported to be 0.4-33%. It has been reported that the incidence of hypocalcemia after thyroidectomy is high when the difference in blood levels of parathyroid hormone and vitamin D is large before and after surgery.

Therefore, it is a very important task to study the effect of using vitamin D3 (cholecalciferol), which has a better effect on the human body, on the prevention of hypocalcemia after total thyroidectomy with a long follow-up period after surgery. The department of surgery in Seoul National University Hospital intends to analyze the preventive effect "D-mac 30,000 IU" on postoperative hypocalcemia and safety of 'D-mac 30,000 IU" through a prospective randomized clinical trial.

The incidence of postoperative hypocalcemia of the group taking orally taking vitamin D3 (cholecalciferol) before surgery will be compared with that of the group not taking vitamin D3 before surgery. Patients who are enrolled in this RCT are allocated to the case group and the control group. Patients in the case group are taking 30,000 IU of vitamin D3 (cholecalciferol) orally, and patients in the control group are not taking any drugs.

Primary endpoint of this study is to evaluate the incidence of hypocalcemia. And secondary endpoints are to evaluate the recovery duration from postoperative hypocalcemia and the risk factors for postoperative hypocalcemia.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Total Thyroidectomy Avitaminosis Calcium Metabolism Disorders Deficiency Diseases Hypocalcemia Malnutrition Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Vitamin D Deficiency Water-Electrolyte Imbalance

Age range

19 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Chung-Ang University Hospital, Seoul, South Korea

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 19 to 70 years old
  • Patients undergoing total thyroidectomy due to thyroid disease
  • Patients who consented to the study and obtained consent for the study

Exclusion criteria

  • Patients with confirmed hypocalcemia or hypercalcemia before surgery
  • Patients receiving calcium or vitamin D treatment before surgery, patients with excessive vitamin D
  • Patients with a previous history of parathyroid disease or a history of cervical irradiation
  • Patients with confirmed parathyroid comorbidity
  • Patients with diseases or conditions that cause hypercalcemia or hypercalciuria (myeloma, bone metastases, or other malignant bone diseases)
  • Patients with confirmed renal dysfunction (glomerular filtration rate <60mL/min/1.73m2) before surgery or with a history of chronic renal failure
  • Renal stone disease patient, kidney stone disease patient
  • Patients with bowel disease that may affect serum vitamin D levels (celiac disease, small intestine resorption disease, small bowel resection history)
  • Patients taking drugs that may affect serum calcium or vitamin D levels (anticonvulsants, bisphosphonates, cisplatin, aminoglycosides, diuretics, proton pump inhibitors, glucocorticoid benzodiazepine derivatives, etc.)
  • Uncontrolled hypertension, diabetes, and clotting disorders
  • Cardiovascular disease (angina pectoris, heart failure, myocardial infarction, coronary artery disease, history of arrhythmia treatment, stroke, transient ischemic attack), and taking medications for arrhythmia
  • Drug Abuse and Alcohol Abuse
  • Patients who participated in other drug clinical trials within 30 days
  • Patients with a history of allergies to drugs
  • For women, pregnant and lactating patients
  • Patients judged unsuitable by the person in charge of the clinical trial
  • Patients with genetic problems such as galactose intolerance, lactose deficiency, or glucose-galactose malabsorption disorder

Treatment and study plan

Cholecalciferol

Drug

Since the concentration of "D-mac 30,000 IU" in the body reaches the maximum in the body around 1 to 3 weeks after administration, the drug is taken once 15 days before the surgery so that the vitamin D3 concentration is maximized at the time of surgery.

In the case of the control group, there is no drug to be taken.

Primary outcomes

  1. Postoperative hypocalcemia

    Time frame: postoperative 1 day

    The incidence of hypocalcemia at postoperative 1 day

  2. Postoperative hypocalcemia

    Time frame: postoperative 2 weeks

    The incidence of hypocalcemia at postoperative 2 weeks

  3. Postoperative hypocalcemia

    Time frame: postoperative 3 months

    The incidence of hypocalcemia at postoperative 3 months

  4. Postoperative hypocalcemia

    Time frame: postoperative 6 months

    The incidence of hypocalcemia at postoperative 6 months

Secondary outcomes

  1. The occurrence of hypocalcemia sign

    Time frame: 1 day, 2 weeks, 3 months, 6 months after surgery

    The results of survey about the occurrence of hypocalcemia sign

  2. Duration of recovery period from postoperative hypocalcemia

    Time frame: 1 day, 2 weeks, 3 months, 6 months after surgery

    Duration for recovery from hypocalcemia after thyroidectomy

  3. Risk factors for developing postoperative hypocalcemia

    Time frame: 1 day, 2 weeks, 3 months, 6 months after surgery

    Risk factors associated with postoperative hypocalcemia

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Collaborators

  • Dalim BioTech Co., Ltd.

Registry information

Official study title

Study for Effectiveness in Prevention of Postoperative Hypocalcemia of Preoperative Oral Supplementation of Vitamin D (D-mac 30,000 IU) in Patients Undergoing Total Thyroidectomy

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Jan 31, 2022
Registry last updated
Apr 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.